Potential utility of GB virus type C as a preventive vaccine for HIV-1

2012 ◽  
Vol 11 (3) ◽  
pp. 335-347 ◽  
Author(s):  
Omar Bagasra ◽  
Alexander U Bagasra ◽  
Muhammad Sheraz ◽  
Donald Gene Pace
2010 ◽  
Vol 185 (7) ◽  
pp. 4496-4505 ◽  
Author(s):  
Emma L. Mohr ◽  
Jinhua Xiang ◽  
James H. McLinden ◽  
Thomas M. Kaufman ◽  
Qing Chang ◽  
...  

2006 ◽  
Vol 103 (42) ◽  
pp. 15570-15575 ◽  
Author(s):  
J. Xiang ◽  
J. H. McLinden ◽  
Q. Chang ◽  
T. M. Kaufman ◽  
J. T. Stapleton
Keyword(s):  
T Cells ◽  
Type C ◽  

AIDS ◽  
2009 ◽  
Vol 23 (17) ◽  
pp. 2277-2287 ◽  
Author(s):  
Maria Teresa Maidana-Giret ◽  
Tânia M Silva ◽  
Mariana M Sauer ◽  
Helena Tomiyama ◽  
José Eduardo Levi ◽  
...  

2000 ◽  
Vol 7 (5) ◽  
pp. 724-727 ◽  
Author(s):  
Ronald B. Moss ◽  
Wieslawa Giermakowska ◽  
Mark R. Wallace ◽  
Jay Savary ◽  
Fred Jensen ◽  
...  

ABSTRACT The discovery of multiple subtypes of human immunodeficiency virus type 1 (HIV-1) worldwide has created new challenges for the development of both therapeutic and preventive AIDS vaccines. We examined T-helper proliferative responses to HIV-1 clade A, B, C, G, and E whole-killed virus and to HIV-1 clade G and B core (p24) antigens in HIV-1-infected subjects taking potent antiviral drugs who received HIV immunogen (Remune) therapeutic vaccination. Subjects who were immunized mounted strong proliferative responses to both whole virus and core antigens of the different clades. These results suggest that a whole-killed immunogen may have broad applications as a therapeutic as well as a preventive vaccine in the current multiclade HIV-1 pandemic.


2009 ◽  
Vol 83 (16) ◽  
pp. 7982-7995 ◽  
Author(s):  
Yuyang Tang ◽  
Ihid Carneiro Leao ◽  
Ebony M. Coleman ◽  
Robin Shepard Broughton ◽  
James E. K. Hildreth

ABSTRACT Human immunodeficiency virus type 1 (HIV-1) relies on cholesterol-laden lipid raft membrane microdomains for entry into and egress out of susceptible cells. In the present study, we examine the need for intracellular cholesterol trafficking pathways with respect to HIV-1 biogenesis using Niemann-Pick type C-1 (NPC1)-deficient (NPCD) cells, wherein these pathways are severely compromised, causing massive accumulation of cholesterol in late endosomal/lysosomal (LE/L) compartments. We have found that induction of an NPC disease-like phenotype through treatment of various cell types with the commonly used hydrophobic amine drug U18666A resulted in profound suppression of HIV-1 release. Further, NPCD Epstein-Barr virus-transformed B lymphocytes and fibroblasts from patients with NPC disease infected with a CD4-independent strain of HIV-1 or transfected with an HIV-1 proviral clone, respectively, replicated HIV-1 poorly compared to normal cells. Infection of the NPCD fibroblasts with a vesicular stomatitis virus G-pseudotyped strain of HIV-1 produced similar results, suggesting a postentry block to HIV-1 replication in these cells. Examination of these cells using confocal microscopy showed an accumulation and stabilization of Gag in LE/L compartments. Additionally, normal HIV-1 production could be restored in NPCD cells upon expression of a functional NPC1 protein, and overexpression of NPC1 increased HIV-1 release. Taken together, our findings demonstrate that intact intracellular cholesterol trafficking pathways mediated by NPC1 are needed for efficient HIV-1 production.


Sign in / Sign up

Export Citation Format

Share Document